Feasibility assessment of modified F0LF0X-6 as adjuvant treatment after resection of liver metastases from colorectal cancer: Analyses of a multicenter phase II clinical trial (Miyagi-HBPCOG Trial-001)

Hepato-Gastroenterology

Volumn 62, Issue 138, 2015, Pages 303-308

  Katayose, Yu ^a   Yamamoto, Kuniharu ^b   Nakagawa, Kei ^a   Takemura, Shinichi ^c   Takahashi, Michinaga ^d   Nakamura, Ryuji ^e   Shimamura, Hiromune ^f   Rikiyama, Toshiki ^g   Egawa, Shinichi ^a   Yoshda, Hiroshi ^a   Motoi, Fuyuhiko ^a   Naitoh, Takeshi ^a   Unno, Michiaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Miyagi Cancer Center   (Japan)

^c Shirakawa Kosei General Hospital   (Japan)

^d South Miyagi Medical Center   (Japan)

^e Tohokukoseinenkin Hospital   (Japan)

^f SENDAI CITY MEDICAL CENTER   (Japan)

^g JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Adjuvant; Colorectal cancer; FOLFOX; Liver metastases

Indexed keywords

FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; HEMOGLOBIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER RECURRENCE; CANCER SURGERY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; COLORECTAL LIVER METASTASIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIVER DYSFUNCTION; LIVER METASTASIS; LIVER RESECTION; LOSS OF APPETITE; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; CLINICAL TRIAL; COLORECTAL TUMOR; DRUG ADMINISTRATION; JAPAN; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; SECONDARY; TIME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HEPATECTOMY; HUMANS; JAPAN; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928552849     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge141044     Document Type: Article

References (24)

1. Choti MA, Sitzmann JV, Tiburi M.F., et al: Trends in long-term survival following liver resection for hepatic colorectal metastases Ann Surg 2002; 235: 759-766
2. Fong Y, Cohen AM, Fortner J.G., et al: Liver resection for colorectal metastases Journal of clinical oncology: official journal of the American Society of Clinical Oncology 1997; 15:938-946
3. Rees M, Plant G, Bygrave S: Late results justify resection for multiple hepatic metastases from colorectal cancer Br J Surg 1997; 84:1136-1140
4. Yiu HY, Whittemore AS, Shibata A: Increasing colorectal cancer incidence rates in Japan Int J Cancer 2004; 109: 777-781
5. Nordlinger B, Sorbye H, Glimelius B., et al: Perioperative chemotherapy with F0LF0X4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial Lancet 2008; 371:1007-1016
6. Lorenz M, Muller HH, Schramm H, et al: Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen) Ann Surg 1998; 228: 756-762
7. Lygidakis NI, Sgourakis G, Vlachos L., et al: Metastatic liver disease of colorectal origin: the value of locoregional immuno-chemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study Hepatogastroenterology 2001; 48:1685-1691
8. Kemeny MM, Adak S, Gray B., et al: Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2002; 20:1499-1505
9. Andre T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl j Med 2004; 350: 2343-2351
10. Tournigand C, Andre T, Achille E., et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2004; 22: 229-237
11. de Gramont A., Figer A, Seymour M., et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2000; 18: 2938-2947
12. Figer A, Perez-Staub N, Carola E., et al: FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study Cancer 2007; 110: 2666-2671
13. Inoue N, Ishida H, Sano M., et al: Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer International journal of clinical oncology / Japan Society of Clinical Oncology 2011; 17(4):341-7
14. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004 CA Cancer J Clin 2004; 54: 8-29
15. Portier G, Elias D, Bouche O., et al: Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2006; 24: 4976-4982
16. Andre T, Boni C, Navarro M., et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2009; 27: 3109-3116
17. Sargent D, Shi Q, Yothers G., et al: Two or three year diseasefree survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12, 676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803 Eur J Cancer 2011; 47: 990-996
18. Amado RG, Wolf M, Peeters M., et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer Journal of clinical oncology: Official journal of the American Society of Clinical Oncology 2008; 26: 1626-1634
19. De Roock W., Jonker DJ, Di Nicolantonio F, et al: Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 2010; 304:1812-1820
20. Haller DC, Tabernero J, Maroun J., et al: Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2011; 29:1465-1471
21. Allegra CJ, Yothers G, O'Connell MJ, et al: Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08 Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2011; 29:11-16
22. Alberts SR, Sargent DJ, Nair S, et al: Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial JAMA 2012; 307:1383-1393
23. Yamashita Y, Adachi E, Toh Y., et al: Risk factors for early recurrence after curative hepatectomy for colorectal liver metastases Surgery today 2011; 41: 526-532
24. Topal B, Kaufman L, Aerts R., et al: Patterns of failure following curative resection of colorectal liver metastases European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2003; 29: 248-253